生产企业：Oxcia AB
OXC-201 is a first-in-class oral OGG1 inhibitor. By targeting central mechanisms behind inflammation and fibrosis, for example effects on oxidative stress, OXC-201 has the potential to influence the underlying processes of the disease.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
